• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于抗磷脂综合征患者机械人工瓣膜血栓形成的新型溶栓方案。

A Novel Thrombolytic Regimen for Mechanical Prosthetic Valve Thrombosis in a Patient With Antiphospholipid Syndrome.

作者信息

Nyembo Philippe F, Buda Kevin G, Hooker Abel, Ayenew Woubeshet

机构信息

Internal Medicine, Hennepin Healthcare, Minneapolis, USA.

Cardiology, Hennepin Healthcare, Minneapolis, USA.

出版信息

Cureus. 2022 Apr 9;14(4):e23979. doi: 10.7759/cureus.23979. eCollection 2022 Apr.

DOI:10.7759/cureus.23979
PMID:35541291
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9084246/
Abstract

Management of mechanical prosthetic valve thrombosis (PVT) includes medical and surgical options. Standard medical treatment involves thrombolytic therapy with repeated slow infusions of low-dose IV tissue plasminogen activator (t-PA). The evidence for managing mechanical PVT that does not respond to the standard t-PA dosing is limited in the setting of an exacerbating hypercoagulable condition. We present a case of a patient with a history of antiphospholipid syndrome who presented with a probable thromboembolic myocardial infarction secondary to a mechanical mitral valve thrombosis that did not improve with systemic anticoagulation and repeated standard t-PA dosing but rapidly resolved with ultraslow, high-dose t-PA.

摘要

机械性人工瓣膜血栓形成(PVT)的管理包括药物和手术选择。标准药物治疗包括使用低剂量静脉组织纤溶酶原激活剂(t-PA)反复缓慢输注进行溶栓治疗。在高凝状态加重的情况下,对于对标准t-PA剂量无反应的机械性PVT的管理证据有限。我们报告一例有抗磷脂综合征病史的患者,该患者因机械性二尖瓣血栓形成继发可能的血栓栓塞性心肌梗死,全身抗凝和反复标准t-PA给药均未改善,但超慢速、高剂量t-PA治疗后迅速缓解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/376e/9084246/d1dbdd0cc821/cureus-0014-00000023979-i06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/376e/9084246/40ca17db03b9/cureus-0014-00000023979-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/376e/9084246/50479fa96c03/cureus-0014-00000023979-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/376e/9084246/f6f3a047d6e0/cureus-0014-00000023979-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/376e/9084246/b387150d4942/cureus-0014-00000023979-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/376e/9084246/c2609ef59e40/cureus-0014-00000023979-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/376e/9084246/d1dbdd0cc821/cureus-0014-00000023979-i06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/376e/9084246/40ca17db03b9/cureus-0014-00000023979-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/376e/9084246/50479fa96c03/cureus-0014-00000023979-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/376e/9084246/f6f3a047d6e0/cureus-0014-00000023979-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/376e/9084246/b387150d4942/cureus-0014-00000023979-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/376e/9084246/c2609ef59e40/cureus-0014-00000023979-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/376e/9084246/d1dbdd0cc821/cureus-0014-00000023979-i06.jpg

相似文献

1
A Novel Thrombolytic Regimen for Mechanical Prosthetic Valve Thrombosis in a Patient With Antiphospholipid Syndrome.一种用于抗磷脂综合征患者机械人工瓣膜血栓形成的新型溶栓方案。
Cureus. 2022 Apr 9;14(4):e23979. doi: 10.7759/cureus.23979. eCollection 2022 Apr.
2
Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial.超慢速溶栓治疗:人工机械瓣膜血栓管理的新策略及预后预测因素:超慢速PROMETEE试验
Am Heart J. 2015 Aug;170(2):409-18. doi: 10.1016/j.ahj.2015.04.025. Epub 2015 May 2.
3
Dual mechanical valve thrombosis resolution through thrombolytics: a case series.通过溶栓剂解决双机械瓣膜血栓形成:病例系列
Eur Heart J Case Rep. 2023 Aug 19;7(9):ytad399. doi: 10.1093/ehjcr/ytad399. eCollection 2023 Sep.
4
Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator.低剂量、缓慢输注组织型纤溶酶原激活剂治疗妊娠合并人工心脏瓣膜血栓形成的溶栓治疗。
Circulation. 2013 Jul 30;128(5):532-40. doi: 10.1161/CIRCULATIONAHA.113.001145. Epub 2013 Jun 28.
5
A Case Series of Obstructive Prosthetic Mitral Valve Thrombosis, Successfully Treated with Low-Dose, Slow Infusion Tissue-Type Plasminogen Activator.低剂量、缓慢输注组织型纤溶酶原激活剂成功治疗梗阻性人工二尖瓣血栓形成的病例系列
J Heart Valve Dis. 2015 May;24(3):353-9.
6
Assessment of Anti-Tissue Type Plasminogen Activator Antibodies in Patients With Prosthetic Heart Valve Thrombosis: The ATA Trial.人工心脏瓣膜血栓形成患者抗组织型纤溶酶原激活剂抗体的评估:ATA试验
J Cardiovasc Pharmacol Ther. 2016 Jul;21(4):372-80. doi: 10.1177/1074248415615236. Epub 2015 Dec 8.
7
Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial.不同经胸超声心动图指导的溶栓方案治疗人工心脏瓣膜血栓的比较:TROIA 试验。
JACC Cardiovasc Imaging. 2013 Feb;6(2):206-16. doi: 10.1016/j.jcmg.2012.10.016.
8
Thrombolysis or Surgery in Patients With Obstructive Mechanical Valve Thrombosis: The Multicenter HATTUSHA Study.机械性瓣膜血栓形成患者的溶栓治疗或手术治疗:多中心 HATTUSHA 研究。
J Am Coll Cardiol. 2022 Mar 15;79(10):977-989. doi: 10.1016/j.jacc.2021.12.027.
9
A rare cause of myocardial infarction: acute inferoposterior myocardial infarction after successful intravenous thrombolytic treatment of mechanical mitral prosthetic valve thrombosis.心肌梗死的罕见病因:机械性二尖瓣人工瓣膜血栓形成经静脉溶栓治疗成功后发生的急性下后壁心肌梗死。
Int J Cardiovasc Imaging. 2005 Oct;21(5):509-12. doi: 10.1007/s10554-004-8331-1.
10
Tenecteplase versus streptokinase thrombolytic therapy in patients with mitral prosthetic valve thrombosis.替奈普酶与链激酶溶栓疗法治疗二尖瓣人工瓣膜血栓形成患者的疗效比较
Indian Heart J. 2018 Jul-Aug;70(4):506-510. doi: 10.1016/j.ihj.2017.10.014. Epub 2017 Nov 14.

本文引用的文献

1
Modified fibrinolytic therapy as treatment of mechanical aortic valve thrombosis.改良纤维蛋白溶解疗法治疗机械性主动脉瓣血栓形成。
SAGE Open Med Case Rep. 2021 Mar 17;9:2050313X21999202. doi: 10.1177/2050313X21999202. eCollection 2021.
2
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2020 ACC/AHA 瓣膜性心脏病患者管理指南:执行摘要:美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
Circulation. 2021 Feb 2;143(5):e35-e71. doi: 10.1161/CIR.0000000000000932. Epub 2020 Dec 17.
3
Mechanical and surgical bioprosthetic valve thrombosis.
机械和外科生物人工瓣膜血栓形成。
Heart. 2017 Dec;103(24):1934-1941. doi: 10.1136/heartjnl-2017-311856. Epub 2017 Aug 5.
4
Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial.超慢速溶栓治疗:人工机械瓣膜血栓管理的新策略及预后预测因素:超慢速PROMETEE试验
Am Heart J. 2015 Aug;170(2):409-18. doi: 10.1016/j.ahj.2015.04.025. Epub 2015 May 2.
5
Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant.抗磷脂综合征和狼疮抗凝物中的华法林监测
Ann Pharmacother. 2014 Nov;48(11):1479-83. doi: 10.1177/1060028014546361. Epub 2014 Aug 7.
6
Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial.不同经胸超声心动图指导的溶栓方案治疗人工心脏瓣膜血栓的比较:TROIA 试验。
JACC Cardiovasc Imaging. 2013 Feb;6(2):206-16. doi: 10.1016/j.jcmg.2012.10.016.
7
Comparison of thrombolysis versus surgery as a first line therapy for prosthetic heart valve thrombosis.比较心脏机械瓣膜血栓形成时溶栓治疗与手术治疗作为一线治疗的差异。
Am J Cardiol. 2011 Jan 15;107(2):275-9. doi: 10.1016/j.amjcard.2010.09.013.
8
Impaired fibrinolysis in the antiphospholipid syndrome.抗磷脂综合征中的纤维蛋白溶解受损。
Curr Rheumatol Rep. 2010 Feb;12(1):53-7. doi: 10.1007/s11926-009-0075-4.
9
Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.抗磷脂抗体与抗磷脂综合征:致病机制
Semin Thromb Hemost. 2008 Apr;34(3):236-50. doi: 10.1055/s-0028-1082267.
10
Comparison of a chromogenic factor X assay with international normalized ratio for monitoring oral anticoagulation therapy.用于监测口服抗凝治疗的显色法X因子检测与国际标准化比值的比较。
Blood Coagul Fibrinolysis. 2008 Sep;19(6):513-7. doi: 10.1097/MBC.0b013e328304e066.